Pharmaceutical intermediates

Tramentinib Dimethyl Sulfoxide Intermediates

5 pharmaceutical intermediates for Tramentinib Dimethyl Sulfoxide. Indication: Glioma; Anaplastic thyroid carcinoma; Solid tumor; Non-small cell lung cancer; Melanoma; Thyroid cancer.

提交项目 All intermediates

About Tramentinib Dimethyl Sulfoxide

Originator: Japan Tobacco Inc
Indication: Glioma; Anaplastic thyroid carcinoma; Solid tumor; Non-small cell lung cancer; Melanoma; Thyroid cancer
Approved Date: 05/29/2013
DS/DP: 06/10/2025

Available intermediates

5 intermediates currently listed for Tramentinib Dimethyl Sulfoxide. Request specifications, documentation or a quotation for any item below.

Tramentinib Dimethyl Sulfoxide intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
2-Fluoro-4-iodoaniline	29632-74-4	/	/
6-Amino-3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-1H-pyrimidine-2,4- dione	871700-28-6	/	/
3-cyclopropyl-1-(2-fluoro-4-iodophenyl)-6-(methylamino)pyrimidine - 2,4(1H,3H)-dione	871700-22-0	/	/
3-Cyclopropyl-1-(2-fluoro-4-iodophenyl)-5-hydroxy-6,8-dimethyl- 1H,8H-pyrido[2,3-d]pyrimidine-2,4,7-trione	871700-24-2	/	/
Trametinib DMSO solvate	1187431-43-1	/	/

Other programs under T

Tazemetostat Hydrobromide Tazobactam Sodium Tegoprazan Tenapanor Hydrochloride Teneligliptin Tetrabenazine Tezacaftor Tianeptine sodium salt

Building toward Tramentinib Dimethyl Sulfoxide?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →